Overview and application of carboplatin

Carboplatin is a widely used anti-cancer drug that belongs to the platinum compound and is mainly used to treat malignant tumors such as ovarian cancer, lung cancer, and head and neck tumors. Its mechanism of action is to inhibit tumor growth by binding to DNA and interfering with the replication of cancer cells. Compared with cisplatin, carboplatin has lower nephrotoxicity and gastrointestinal side effects, but myelosuppression (such as thrombocytopenia) is more obvious. This article will focus on pharmacological properties, clinical applications, adverse reactions and manufacturers to help readers fully understand this important anti-tumor drug.

Pharmacological properties and mechanism of action

Carboplatin blocks the division of cancer cells by forming cross-links within the DNA chain. Its chemical stability is higher than that of cisplatin, and it needs to be converted into an active form in the body to function. Pharmacokinetics show that carboplatin is mainly excreted through the kidneys, and patients with renal insufficiency need to adjust the dose. Research shows (quoted fromNew England Journal of Medicine), carboplatin combined with paclitaxel is the first-line treatment for ovarian cancer, with an effective rate of 60%-70%. Its myelosuppressive properties require regular monitoring of blood routine, with particular attention to platelet and neutrophil levels.

Clinical applications and treatment options

The indications for carboplatin cover a variety of solid tumors, including:

The American Society of Clinical Oncology (ASCO) guidelines emphasize that carboplatin dosage should be based onAUC (area under the curve)Calculated, individualized medication can reduce the risk of toxicity.

Adverse reactions and medication management

Common side effects include bone marrow suppression (the incidence is about 75%), nausea and vomiting (20%-30%), and neurotoxicity and nephrotoxicity are significantly lower than cisplatin. Clinical recommendations:

• Use granulocyte colony-stimulating factor (G-CSF) within 24 hours after chemotherapy to prevent infection
• Consider platelet transfusion when platelets are <50×10⁹/L

ChinaNational Cancer CenterData show that the incidence of serious adverse reactions can be reduced to less than 5% after standardized treatment.

Manufacturer and drug information

Major domestic manufacturers include:

Origin of original research drugBristol-Myers SquibbDeveloped, the patent has expired. It should be noted that differences in excipients from different manufacturers may affect the incidence of allergic reactions.

Summary and Outlook

As a representative of the second generation platinum drugs, carboplatin has achieved a good balance between efficacy and safety. With the development of nanocarrier technology (such as liposomal carboplatin), it is expected that toxicity will be further reduced in the future. Patients must strictly follow the medicationNCCN Guidelines, combined with genetic testing (such as BRCA mutation) to achieve precise treatment. Clinicians should weigh the risk of myelosuppression, especially in elderly patients and patients with poor physical status who require individualized assessment.

Quote sources:
1. "New England Journal of Medicine": Phase III clinical trial data of carboplatin combination regimen for the treatment of ovarian cancer
2. National Cancer Center: 2022 White Paper on the Management of Adverse Reactions of Cancer Chemotherapy in China
3. American Society of Clinical Oncology (ASCO) 2023 Guidelines for the Diagnosis and Treatment of Ovarian Cancer